AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.095

-0.001-1.04%

Volume:327.13K

Turnover:31.30K

Market Cap:65.42M

PE:-2.79

High:0.098

Open:0.097

Low:0.095

Close:0.096

52wk High:0.185

52wk Low:0.079

Shares:688.63M

Float Shares:351.37M

Volume Ratio:0.91

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.034

EPS(LYR):-0.034

ROE:-254.33%

ROA:-136.74%

PB:23.19

PE(LYR):-2.79

Loading ...

Overview Company News Filings

Neurizon Therapeutics Ltd-Change of Director's Interest Notice

THOMSON REUTERS

Neurizon Therapeutics Ltd-Neurizon Completes Entitlement Offer

THOMSON REUTERS

Neurizon Therapeutics Ltd-Change of Director's Interest Notice

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon® Across All Priority Global Markets

Neurizon Therapeutics Ltd - Secured Registered Trademark Protection for Neurizon® Across All Priority Global Markets

THOMSON REUTERS

BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request

Neurizon Therapeutics Ltd - Updates on Nuz-001 Development for ALS

THOMSON REUTERS

Neurizon Therapeutics Ltd - US FDA Denies Fast Track Designation for Nuz-001

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via Placement

BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement

Neurizon Therapeutics Ltd - Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Seeks Trading Halt

Neurizon Therapeutics - Seeks Trading Halt Pending Proposed Capital Raising Announcement

THOMSON REUTERS

ASX Penny Stocks To Consider In December 2025

Simply Wall St.

FDA Clears Nuz-001 for Entry Into Healey ALS Platform Trial

THOMSON REUTERS

Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial

MT Newswires Live

BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use

Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%

MT Newswires Live

Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer

Elanco Executive Appointed as Neurizon's Board Observer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.095,"timestamp":1771564320000,"preClose":0.096,"halted":0,"volume":327133,"delay":0,"changeRate":-0.010416666666666676,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":688628681,"eps":-0.034045,"marketStatus":"Market Closed","change":-0.001,"latestTime":"02-20 16:12:00 AEDT","open":0.097,"high":0.098,"low":0.095,"amount":31304,"amplitude":0.03125,"askPrice":0.098,"askSize":70462,"bidPrice":0.095,"bidSize":969954,"shortable":3,"etf":0,"ttmEps":-0.034045,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.096,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0.9131747974858712,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-136.74%","roe":"-254.33%","lyrEps":-0.034045,"volumeRatio":0.9131747974858712,"shares":688628681,"dividePrice":0,"high":0.098,"amplitude":0.03125,"preClose":0.096,"low":0.095,"week52Low":0.079,"pbRate":"23.19","psRate":"42.54","week52High":0.185,"institutionHeld":0,"latestPrice":0.095,"committee":0.86455,"eps":-0.034045,"divideRate":0,"volume":327133,"delay":0,"ttmEps":-0.034045,"open":0.097,"prevYearClose":0.085,"prevWeekClose":0.093,"prevMonthClose":0.09,"prevQuarterClose":0.085,"fiveDayClose":0.093,"twentyDayClose":0.084,"sixtyDayClose":0.11,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608128842","title":"Neurizon Therapeutics Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2608128842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608128842?lang=en_us&edition=fundamental","pubTime":"2026-02-03 14:53","pubTimestamp":1770101598,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUE8LTS7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2606938224","title":"Neurizon Therapeutics Ltd-Neurizon Completes Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606938224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606938224?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:56","pubTimestamp":1769468199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUE6SWHXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2605448501","title":"Neurizon Therapeutics Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2605448501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605448501?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:08","pubTimestamp":1769119728,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUE62QT70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2604152626","title":"BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon® Across All Priority Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2604152626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604152626?lang=en_us&edition=fundamental","pubTime":"2026-01-20 09:20","pubTimestamp":1768872022,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon Across All Priority Global MarketsJan 20  - Neurizon Therapeutics Ltd NUZ.AX:SECURED REGISTERED TRADEMARK PROTECTION FOR NEURIZON ACROSS ALL PRIORITY GLOBAL MARKETSFurther company coverage: NUZ.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YK0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2604815662","title":"Neurizon Therapeutics Ltd - Secured Registered Trademark Protection for Neurizon® Across All Priority Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2604815662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604815662?lang=en_us&edition=fundamental","pubTime":"2026-01-20 06:49","pubTimestamp":1768862945,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YK0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2600034250","title":"BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034250","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034250?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:40","pubTimestamp":1767310806,"startTime":"0","endTime":"0","summary":"BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request** Shares of Australia's Neurizon Therapeutics NUZ.AX fall as much as 5.9% to A$0.08, their lowest level since November 23, 2023** Marks steepest intraday pct fall since December 23** Biotech company says the U.S. Food and Drug Administration denies its request for Fast Track Designation** Request was for its investigational new treatment for Amyotrophic Lateral Sclerosis, NUZ-001  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nL6N3Y206B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2600031619","title":"Neurizon Therapeutics Ltd - Updates on Nuz-001 Development for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031619?lang=en_us&edition=fundamental","pubTime":"2026-01-02 05:47","pubTimestamp":1767304037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE4HMJT5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2600031611","title":"Neurizon Therapeutics Ltd - US FDA Denies Fast Track Designation for Nuz-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031611?lang=en_us&edition=fundamental","pubTime":"2026-01-02 05:47","pubTimestamp":1767304037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE4HMJT5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2593545420","title":"BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545420","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545420?lang=en_us&edition=fundamental","pubTime":"2025-12-23 09:13","pubTimestamp":1766452424,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via PlacementDec 23 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:FIRM COMMITMENTS TO RAISE A$7.1 MILLION VIA PLACEMENT AT A$0.08 PER SHAREFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XS0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2593925459","title":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593925459","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593925459?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:03","pubTimestamp":1766448209,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement** Shares of Australia's Neurizon Therapeutics NUZ.AX slump as much as 23.6% to A$0.084, their lowest since late Novem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2593455719","title":"Neurizon Therapeutics Ltd -  Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455719","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455719?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:50","pubTimestamp":1766443838,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2592972182","title":"BRIEF-Neurizon Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592972182?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:14","pubTimestamp":1766096080,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Seeks Trading Halt Dec 19 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:SEEKS TRADING HALT PENDING PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2592182944","title":"Neurizon Therapeutics - Seeks Trading Halt Pending Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182944?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:14","pubTimestamp":1766096047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2590422573","title":"ASX Penny Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590422573","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590422573?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:05","pubTimestamp":1765505127,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or newer companies, continue to attract attention for their potential growth and value propositions. Despite being considered an outdated term by some, these stocks remain relevant as they can offer unique opportunities for those looking to explore under-the-radar investments with strong financial...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MTO.AU","BK7077","BK7055","IGL.AU","BK7048","BK7128","BK7050","WAF.AU","GWA.AU","BK7104","BK7508","BK7501","MLX.AU","BK7095","BK7096","DXB.AU","BK7111","BK7506","AAL.AU","EDU.AU","VRS.AU","SSM.AU","BK7012","BK7132","DSK.AU","NUZ.AU","BK7507","BK7067","BK7143","BK7045","EZZ.AU"],"gpt_icon":0},{"id":"2590493895","title":"FDA Clears Nuz-001 for Entry Into Healey ALS Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590493895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590493895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 04:50","pubTimestamp":1765486245,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH1E2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2590698455","title":"Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590698455","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590698455?lang=en_us&edition=fundamental","pubTime":"2025-12-11 12:19","pubTimestamp":1765426747,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said that the Sean M. Healey & AMG Center for ALS at Mass General Brigham in Massachusetts received clearance from the US Food and Drug Administration to proceed with the NUZ-001 regimen, Neurizon's drug candidate for the treatment of amyotrophic lateral sclerosis , in the Healey ALS Platform trial after the regulator completed a 30-day review, according to a Thursday Australian bourse filing.The US FDA's acceptance of the protocol amendment allows the firm and the clinical trial team to progress to the next operational phases, including submissions to the Institutional Review Board, activation of clinical trial sites, and initiation of study start-up activities.The trial tests and evaluates multiple investigational drugs simultaneously, sharing infrastructure across trial sites.The first patients are expected to be enrolled early in 2026, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2590568384","title":"BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568384","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590568384?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:13","pubTimestamp":1765419221,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use** Shares of Australia's Neurizon Therapeutics NUZ.AX jump as much as 8.7% to A$0.125, their highest since November 20** Neurodegenerative disease-focused biotech co says the U.S. Food and Drug Administration has cleared the use of its \"NUZ001 regimen\" in the HEALEY ALS platform trial** NUZ-001 is a potential treatment option for people living with amyotrophic lateral sclerosis , a progressive neurodegenerative disorder     ** YTD, shares down 32.4%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH050:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2588079530","title":"Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588079530","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588079530?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:42","pubTimestamp":1764812538,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  has completed the manufacturing of three planned registration batches of its NUZ-001 tablets for the treatment of Amyotrophic Lateral Sclerosis , according to a Thursday filing with the Australian bourse.The company can now pursue a Rolling Review of the New Drug Application , allowing the US Food and Drug Administration to review chemistry, manufacturing, and controls details before the full NDA submission, the filing said.The batches have been placed on both long-term and accelerated stability programs to establish product shelf-life, the filing added.Neurizon said it is on track to start patient enrolment in the HEALEY ALS platform trial in the first quarter of 2026, the company said.Shares of the company fell 5% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2586296817","title":"Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586296817","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586296817?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:17","pubTimestamp":1764199037,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd. has appointed Justine Conway, Global Head of Business Development at Elanco Animal Health, as a Board Observer. Conway will participate in Neurizon's Board and committee meetings as Elanco's designated representative, bringing extensive experience in business development and strategic partnerships to the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5C3NYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK4561","LU1941712264.USD","LU1941712348.USD","ELAN","NUZ.AU","BK4007"],"gpt_icon":0},{"id":"2586329681","title":"Elanco Executive Appointed as Neurizon's Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586329681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586329681?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:16","pubTimestamp":1764198985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA2494QB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}